Melanoma. Guidelines for diagnosis and therapy;Das melanom. Richtlinien für diagnose und therapie

Tagliche Praxis

Volumn 46, Issue 1, 2005, Pages 35-52

  Zalaudek, I ^b   Argenziano, G ^b   Ferrara, G ^b   Fink Puches, R ^b   Kerl, H ^b   Richtig, E ^b   Smolle, J ^b   Di Stefani, A ^b   Soyer, H P ^b   Wolf, I H ^b   Hofmann Wellenhof, R ^a  

^a Universitatsklinik   (Austria)

^b NONE

Author keywords

Chemotherapy; Dermoscopy; Epidemiology; Melanoma; Nevus; Risk factors

Indexed keywords

CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER SURGERY; EPILUMINESCENCE MICROSCOPY; EVIDENCE BASED MEDICINE; LYMPH NODE DISSECTION; MELANOMA; METASTASIS; PRACTICE GUIDELINE; REVIEW; SENTINEL LYMPH NODE BIOPSY;

EID: 20144379259     PISSN: 0494464X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Koh HK, et al. Who discovers melanoma? J Am Acad Dermatol 1992; 26: 914-919.
2. Devesa SS, et al. Recent cancer trends in the United States. J Natl Cancer Inst 1995; 87: 175-182.
3. Burton RC, et al. An analysis of a melanoma epidemic. Int J Cancer 1993; 55: 765-770.
4. Horn-Ross P, et al. Temporal trends in the incidence of cutaneous malignant melanoma among Caucasians in the San Francisco Oakland MSA. Cancer Causes Control 1991; 2: 299-305.
5. Koh HK. Cutaneous melanoma. N Engl J Med 1991; 325: 171-182.
6. Dennis LK. Analysis of the Melanoma Epidemic, Both Apparent and Real. Arch Dermatol 1999; 135: 275-280.
7. Volkenandt M, Plewig GW, Hrsg. Maligne Melanome. 5. Aufl. München: Zuckschwerdt; 2000.
8. Balch CM, et al. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 2001; 19: 3635-3648.
9. Herd RM, et al. Cutaneous malignant melanoma: publicity, screening clinics and survival - the Edinburgh experience. Br J Dermatol 1995; 132: 563-570.
10. Burton RC, et al. An analysis of a melanoma epidemic. Int J Cancer 1993; 55: 765-770.
11. Hall HI, et al. Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol 1999; 40: 35-42.
12. Rigel DS. Identification of those at highest risk for development of malignant melanoma. Adv Dermatol 1995; 10: 151-170.
13. Clark WH jr, et al. Origin of familial malignant melanoma from heritable melanocytic lesions: »the B-K mole syndrome«. Arch Dermatol 1978; 114: 732-738.
14. Rigel DS, et al. Dysplastic nevi: markers for increased risk for melanoma. Cancer 1989; 63: 386-389.
15. Clark WH jr, et al. A study of tumor progression. The precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1986; 15: 1147-1165.
16. Clark WH jr, Elder DE, Van Horn M. The biologic forms of malignant melanoma. Hum Pathol 1986; 17: 443-450.
17. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin 1985; 35: 130-151.
18. Guibert P, et al. Melanoma screening: report of a survey in occupational medicine. Arch Dermatol 2000; 136: 199-202.
19. Koh HK, et al. Lentigo maligna melanoma has no better prognosis than other types of melanoma. J Clin Oncol 1984; 2: 994-1001.
20. Stolz W, et al. ABCD rule of dermatoscopy: a new practical method for early recognition of malignant melanoma. Eur J Dermatol 1994; 4: 521-527.
21. Menzies SW, et al. Frequency and morphologic characteristics of invasive melanomas lacking specific surface microscopic features. Arch Dermatol 1996; 132: 1178-1182.
22. Argenziano G, et al. Epiluminescence microscopy for the diagnosis of doubtful melanocytic skin lesions. Comparison of the ABCD rule of dermatoscopy and a new 7-point checklist based on pattern analysis. Arch Dermatol 1998; 134: 1563-1570.
23. Soyer HP, et al. Three-point checklist of dermoscopy. Dermatology 2004; 208: 27-31.
24. Clark WH jr, et al. The histogenesis and biologic behavior of primary human malignant melanoma of the skin. Cancer Res 1969; 29: 705.
25. Breslow A. Prognostic factors in the treatment of cutaneous melanoma. J Cutan Pathol 1979; 6: 208.
26. Veronesi U, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med-1988; 318: 1159-1162. (Published erratum appears in N Engl J Med 1991; 325: 292.)
27. Veronesi U, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med-1988; 318: 1159-1162. (Published erratum appears in N Engl J Med 1991; 325: 292.)
28. Sober AJ, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001; 45: 579-586.
29. Veronesi U, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977; 297: 627-630.
30. Sim FH, et al. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomised study. Mayo Clin Proc 1986; 61: 697-705.
31. Morton DL, et al. Technical details of intra-operative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-399.
32. Kirkwood JM, et al. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trail EST 1684. J Clin Oncol 1996; 14: 7.
33. Wonorm IL, et al. Surgery as palliative treatment for distant metastases of melanoma. Ann Surg 1986; 204: 181-185.
34. Houghton AN, Legha S, Bajorin DF. Chemotherapy for metastatic melanoma. In: Balch CM, et al. editors. Cutaneous melanoma. Philadelphia: Lippincott; 1992. p. 498.
35. Saxman SB, et al. Phase III randomised trial of DTIC, Cisplatin, BCNU and Tamoxifen versus DTIC alone in patients with metastatic melanoma (abstract). Proc Am Soc Clin Oncol 1999; 18: 2068a.
36. Legha SS, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbacine, interferon alpha, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998; 16: 1752-1759.
37. Legha SS, Buzaid AC. Role of recombinant interleukin-2 in combination with interferon alpha and chemotherapy in the treatment of advanced melanoma. Semin Oncol 1993; 20: 27-32.
38. Livingston P, Sznol M. Vaccine therapy in cutaneous Melanoma. 3rd ed. St. Louis: Quality Medical; 1998. p. 437-450.
39. Sondak VK, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with allogenic tumor vaccine: overall results of a randomised trial of the Southwest Oncology Group. J Clin Oncol 2002; 20: 2058-2066.
40. Slingluff CL jr, et al. Phase I trial of a melanoma vaccine with gp 100 (280-288) peptide and tetanus helper peptide in adjuvant: immunological and clinical outcomes. Clin Cancer Res 2001; 7: 3012-3024.
41. Nestle FO, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1984; 4: 328-332.
42. Jansen B, et al. Bcl-2 antisense therapy chemosentizies human melanoma in SCID mice. Nature Med 1998; 4: 232-234.
43. Martini L, et al. First recurrence analysis of 840 cutaneous melanomas: a proposal for follow-up schedule. Tumori 1994; 80: 188-197.
44. McCarthy WH, et al. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow up study. Surg Gynecol Obstet 1988; 166: 497-502.
45. Terhune MH, Swanson N, Johnson TM. Use of chest radiographs in the initial evaluation of patients with localized melanoma. Arch Dermatol 1998; 134: 638-643.
46. Jillella A, Mani S, Nair B. The role for close follow-up of melanoma patients with AJCC stages I-III: a preliminary analysis. Proc Am Soc Clin Oncol 1995; 14: 413.
47. Weiss M, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanoma. JAMA 1995; 274: 1703-1705.
48. Damian DL. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996; 6: 325-329.